Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels.
about
Evolving targets for lipid-modifying therapyStimulation of Liver X Receptor Has Potent Anti-HIV Effects in a Humanized Mouse Model of HIV Infection.Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 MiceSex-Specific Differences in Hepatic Fat Oxidation and Synthesis May Explain the Higher Propensity for NAFLD in Men.Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.Targeting high density lipoproteins in the prevention of cardiovascular disease?Re-adopting classical nuclear receptors by cholesterol metabolites.LXRβ/estrogen receptor-α signaling in lipid rafts preserves endothelial integrity.Liver X receptors, atherosclerosis and inflammation.Alterations in bile acid synthesis in carriers of hepatocyte nuclear factor 1α mutations.Discovery of Highly Potent Liver X Receptor β Agonists.Retracted: Advances in the physiological and pathological implications of cholesterol.The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects.
P2860
Q34880292-04BF5A68-5096-44D4-83B0-7E7B3AA8CA57Q35962036-5D5D1E41-AA53-41D6-8CA5-872613CA07B8Q36065117-C6205FB9-20E8-4477-AA44-170C9B4CB6C0Q36339964-4613F96C-5217-40FC-B332-DCDB43BF0525Q36419283-C718E4A7-7583-4740-856E-6F27B8342E14Q36453173-41CE3CD3-94B7-4832-893A-267CFDD423D1Q36494078-014DCB14-E210-4780-BCF4-6FB52D053330Q37052905-FA80A405-E728-4FE8-834E-F363C90B9689Q37993787-91DB2F78-4FE3-441B-A16A-03A3E13E769EQ44839903-DFBD70D6-FC8B-4EDD-95EA-F8797397CE93Q45162592-BC045123-23AF-4A35-81B3-55C940B7DFEDQ46069993-A601C346-AF90-410E-976A-27B51203C07CQ53615353-D21154C7-D960-4E88-86AE-242B6D49DBD9
P2860
Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Low dose of the liver X recept ...... or plasma triglyceride levels.
@ast
Low dose of the liver X recept ...... or plasma triglyceride levels.
@en
Low dose of the liver X recept ...... or plasma triglyceride levels.
@nl
type
label
Low dose of the liver X recept ...... or plasma triglyceride levels.
@ast
Low dose of the liver X recept ...... or plasma triglyceride levels.
@en
Low dose of the liver X recept ...... or plasma triglyceride levels.
@nl
prefLabel
Low dose of the liver X recept ...... or plasma triglyceride levels.
@ast
Low dose of the liver X recept ...... or plasma triglyceride levels.
@en
Low dose of the liver X recept ...... or plasma triglyceride levels.
@nl
P2093
P2860
P921
P1476
Low dose of the liver X recept ...... or plasma triglyceride levels
@en
P2093
El Lindstedt
J Oscarsson
Jwa van der Hoorn
M Voskuilen
Mea Bekkers
P2860
P304
P356
10.1111/J.1476-5381.2010.01168.X
P407
P577
2011-04-01T00:00:00Z